Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma

Hye Ryun Kim, ByoungChul Cho, Hyo Sup Shim, Sun Min Lim, Se Kyu Kim, Joon Chang, Dae Joon Kim, Joo Hang Kim

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, ~20-30% exhibit de novo resistance to EGFR-tyrosine kinase inhibitor (TKI). The aim of this study was to examine whether mutations in the EGFR-downstream genes may be associated with de novo resistance to EGFR-TKIs in EGFR mutation-positive patients. Materials and methods: Sixty-eight never-smoker adenocarcinoma patients with an activating EGFR mutation were included in the mutational analysis and 55 patients treated with EGFR-TKIs were analyzed for the treatment outcomes to EGFR-TKIs. We concurrently analyzed mutations in PIK3CA, PTEN, AKT and STK11, which are all EGFR-downstream genes. Mutations in PIK3CA, PTEN, AKT, and STK11 were analyzed by polymerase chain reaction-based sequencing. Results: PIK3CA mutations were detected in 4.4% (3/68) of patients, PTEN mutations in 16.1% (11/68), AKT mutations in 5.9% (4/68), and STK11 mutations in 13.2% (9/68). One patient with an activating exon 21 L858R mutation concomitantly had an exon 20 T790M mutation in EGFR. The proportion of patients who had mutations in EGFR-downstream genes was 32.4% (22/68). When we analyzed the treatment outcome of 55 patients treated with EGFR-TKI, the presence of mutations in EGFR-downstream genes correlated with a poor overall response rate to EGFR-TKIs (63.6 vs.14.5% in patients with mutation in EGFR-downstream gene, P< 0.0001), shorter median progression-free survival (12.0 vs. 3.0 months, P= 0.060), and shorter median overall survival (18.9 vs. 25.0 months, P= 0.048). Conclusion: Mutations in the EGFR-downstream genes may confer resistance to EGFR-TKIs and result in poor treatment outcomes in never-smoker adenocarcinoma patients with activating EGFR mutations.

Original languageEnglish
Pages (from-to)374-382
Number of pages9
JournalLung Cancer
Volume83
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
Adenocarcinoma of lung
Exons
Adenocarcinoma
Non-Small Cell Lung Carcinoma
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Kim, Hye Ryun ; Cho, ByoungChul ; Shim, Hyo Sup ; Lim, Sun Min ; Kim, Se Kyu ; Chang, Joon ; Kim, Dae Joon ; Kim, Joo Hang. / Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. In: Lung Cancer. 2014 ; Vol. 83, No. 3. pp. 374-382.
@article{c7806e32eccd4d62bdd5d007d1282488,
title = "Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma",
abstract = "Objectives: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, ~20-30{\%} exhibit de novo resistance to EGFR-tyrosine kinase inhibitor (TKI). The aim of this study was to examine whether mutations in the EGFR-downstream genes may be associated with de novo resistance to EGFR-TKIs in EGFR mutation-positive patients. Materials and methods: Sixty-eight never-smoker adenocarcinoma patients with an activating EGFR mutation were included in the mutational analysis and 55 patients treated with EGFR-TKIs were analyzed for the treatment outcomes to EGFR-TKIs. We concurrently analyzed mutations in PIK3CA, PTEN, AKT and STK11, which are all EGFR-downstream genes. Mutations in PIK3CA, PTEN, AKT, and STK11 were analyzed by polymerase chain reaction-based sequencing. Results: PIK3CA mutations were detected in 4.4{\%} (3/68) of patients, PTEN mutations in 16.1{\%} (11/68), AKT mutations in 5.9{\%} (4/68), and STK11 mutations in 13.2{\%} (9/68). One patient with an activating exon 21 L858R mutation concomitantly had an exon 20 T790M mutation in EGFR. The proportion of patients who had mutations in EGFR-downstream genes was 32.4{\%} (22/68). When we analyzed the treatment outcome of 55 patients treated with EGFR-TKI, the presence of mutations in EGFR-downstream genes correlated with a poor overall response rate to EGFR-TKIs (63.6 vs.14.5{\%} in patients with mutation in EGFR-downstream gene, P< 0.0001), shorter median progression-free survival (12.0 vs. 3.0 months, P= 0.060), and shorter median overall survival (18.9 vs. 25.0 months, P= 0.048). Conclusion: Mutations in the EGFR-downstream genes may confer resistance to EGFR-TKIs and result in poor treatment outcomes in never-smoker adenocarcinoma patients with activating EGFR mutations.",
author = "Kim, {Hye Ryun} and ByoungChul Cho and Shim, {Hyo Sup} and Lim, {Sun Min} and Kim, {Se Kyu} and Joon Chang and Kim, {Dae Joon} and Kim, {Joo Hang}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.lungcan.2013.12.011",
language = "English",
volume = "83",
pages = "374--382",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. / Kim, Hye Ryun; Cho, ByoungChul; Shim, Hyo Sup; Lim, Sun Min; Kim, Se Kyu; Chang, Joon; Kim, Dae Joon; Kim, Joo Hang.

In: Lung Cancer, Vol. 83, No. 3, 01.03.2014, p. 374-382.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma

AU - Kim, Hye Ryun

AU - Cho, ByoungChul

AU - Shim, Hyo Sup

AU - Lim, Sun Min

AU - Kim, Se Kyu

AU - Chang, Joon

AU - Kim, Dae Joon

AU - Kim, Joo Hang

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Objectives: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, ~20-30% exhibit de novo resistance to EGFR-tyrosine kinase inhibitor (TKI). The aim of this study was to examine whether mutations in the EGFR-downstream genes may be associated with de novo resistance to EGFR-TKIs in EGFR mutation-positive patients. Materials and methods: Sixty-eight never-smoker adenocarcinoma patients with an activating EGFR mutation were included in the mutational analysis and 55 patients treated with EGFR-TKIs were analyzed for the treatment outcomes to EGFR-TKIs. We concurrently analyzed mutations in PIK3CA, PTEN, AKT and STK11, which are all EGFR-downstream genes. Mutations in PIK3CA, PTEN, AKT, and STK11 were analyzed by polymerase chain reaction-based sequencing. Results: PIK3CA mutations were detected in 4.4% (3/68) of patients, PTEN mutations in 16.1% (11/68), AKT mutations in 5.9% (4/68), and STK11 mutations in 13.2% (9/68). One patient with an activating exon 21 L858R mutation concomitantly had an exon 20 T790M mutation in EGFR. The proportion of patients who had mutations in EGFR-downstream genes was 32.4% (22/68). When we analyzed the treatment outcome of 55 patients treated with EGFR-TKI, the presence of mutations in EGFR-downstream genes correlated with a poor overall response rate to EGFR-TKIs (63.6 vs.14.5% in patients with mutation in EGFR-downstream gene, P< 0.0001), shorter median progression-free survival (12.0 vs. 3.0 months, P= 0.060), and shorter median overall survival (18.9 vs. 25.0 months, P= 0.048). Conclusion: Mutations in the EGFR-downstream genes may confer resistance to EGFR-TKIs and result in poor treatment outcomes in never-smoker adenocarcinoma patients with activating EGFR mutations.

AB - Objectives: Among non-small cell lung cancer (NSCLC) patients harboring activating epidermal growth factor receptor (EGFR) mutations, ~20-30% exhibit de novo resistance to EGFR-tyrosine kinase inhibitor (TKI). The aim of this study was to examine whether mutations in the EGFR-downstream genes may be associated with de novo resistance to EGFR-TKIs in EGFR mutation-positive patients. Materials and methods: Sixty-eight never-smoker adenocarcinoma patients with an activating EGFR mutation were included in the mutational analysis and 55 patients treated with EGFR-TKIs were analyzed for the treatment outcomes to EGFR-TKIs. We concurrently analyzed mutations in PIK3CA, PTEN, AKT and STK11, which are all EGFR-downstream genes. Mutations in PIK3CA, PTEN, AKT, and STK11 were analyzed by polymerase chain reaction-based sequencing. Results: PIK3CA mutations were detected in 4.4% (3/68) of patients, PTEN mutations in 16.1% (11/68), AKT mutations in 5.9% (4/68), and STK11 mutations in 13.2% (9/68). One patient with an activating exon 21 L858R mutation concomitantly had an exon 20 T790M mutation in EGFR. The proportion of patients who had mutations in EGFR-downstream genes was 32.4% (22/68). When we analyzed the treatment outcome of 55 patients treated with EGFR-TKI, the presence of mutations in EGFR-downstream genes correlated with a poor overall response rate to EGFR-TKIs (63.6 vs.14.5% in patients with mutation in EGFR-downstream gene, P< 0.0001), shorter median progression-free survival (12.0 vs. 3.0 months, P= 0.060), and shorter median overall survival (18.9 vs. 25.0 months, P= 0.048). Conclusion: Mutations in the EGFR-downstream genes may confer resistance to EGFR-TKIs and result in poor treatment outcomes in never-smoker adenocarcinoma patients with activating EGFR mutations.

UR - http://www.scopus.com/inward/record.url?scp=84894277789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894277789&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.12.011

DO - 10.1016/j.lungcan.2013.12.011

M3 - Article

C2 - 24468202

AN - SCOPUS:84894277789

VL - 83

SP - 374

EP - 382

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -